Transgene Biotek Ltd
BSE:526139

Watchlist Manager
Transgene Biotek Ltd Logo
Transgene Biotek Ltd
BSE:526139
Watchlist
Price: 6.94 INR -6.34% Market Closed
Market Cap: 525.8m INR
Have any thoughts about
Transgene Biotek Ltd?
Write Note

Transgene Biotek Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Transgene Biotek Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Transgene Biotek Ltd
BSE:526139
Total Equity
â‚ą108.3m
CAGR 3-Years
-14%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
Bharat Immunologicals and Biologicals Corporation Ltd
BSE:524663
Total Equity
â‚ą787.1m
CAGR 3-Years
71%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Z
Zenotech Laboratories Ltd
BSE:532039
Total Equity
â‚ą931.7m
CAGR 3-Years
21%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Hester Biosciences Ltd
NSE:HESTERBIO
Total Equity
â‚ą3B
CAGR 3-Years
7%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Biocon Ltd
NSE:BIOCON
Total Equity
â‚ą197.8B
CAGR 3-Years
36%
CAGR 5-Years
25%
CAGR 10-Years
20%
Panacea Biotec Ltd
NSE:PANACEABIO
Total Equity
â‚ą8.3B
CAGR 3-Years
N/A
CAGR 5-Years
24%
CAGR 10-Years
N/A
No Stocks Found

Transgene Biotek Ltd
Glance View

Market Cap
525.8m INR
Industry
Biotechnology

Transgene Biotek Ltd. is a biotechnology company, which manufactures and sells diagnostic kits. The company is headquartered in Medak, Telangana. The firm is engaged in a single business segment of Bulk Drugs. Its portfolio of products includes oncology, auto-immunity, drug delivery and biogenerics. The firm offers TrabiAAV, which is a platform for the delivery of micro ribonucleic acids (miRNAs), short hairpin RNA (ShRNAs), immunogens developing clinical significance in gene therapy. The company also offers monoclonal antibody therapy is the use of monoclonal antibodies to specifically bind to target cells. Its TrabiORAL focused on delivering proteins and peptides orally for a variety of human diseases. Its TBL-0404, is used for the treatment of metastatic liver cancer. Its TBL-1203, is used to strengthen cell-mediated immunity and complete elimination of the human immunodeficiency virus (HIV), without any need for retroviral drug therapy. Its Tacrolimus is a drug that suppresses the immune system and is mainly used to prevent rejection of transplanted organs.

TRABI Intrinsic Value
0.29 INR
Overvaluation 96%
Intrinsic Value
Price

See Also

What is Transgene Biotek Ltd's Total Equity?
Total Equity
108.3m INR

Based on the financial report for Sep 30, 2024, Transgene Biotek Ltd's Total Equity amounts to 108.3m INR.

What is Transgene Biotek Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
-22%

Over the last year, the Total Equity growth was -2%. The average annual Total Equity growth rates for Transgene Biotek Ltd have been -14% over the past three years , -22% over the past five years .

Back to Top